Erratum to: PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: *In Vitro* Evaluation and *In Vivo* Tumor Accumulation

Saijie Zhu • Minghuang Hong • Lihong Zhang • Guotao Tang • Yanyan Jiang • Yuanying Pei

Published online: 20 July 2010
© Springer Science+Business Media, LLC 2010

Erratum to: Pharm Res
DOI 10.1007/s11095-009-9992-1

NOTICE OF DUPLICATE PUBLICATION

Our recent article published in *Pharmaceutical Research* (1) was prepared simultaneously with an article published in *Biomaterials* (2), both examining the effects of an identical batch of PEGylated PAMAM dendrimer-doxorubicin conjugates on tumor accumulation. The polymer synthesis and characterization sections in both articles were inadvertently duplicated, namely Figures 1 and 2 in *Pharmaceutical Research* and Figures 2 and 3 in *Biomaterials*.

We would like to apologize to the editors and readers of *Biomaterials* and *Pharmaceutical Research* for any ambiguity this may have caused.

REFERENCES

- Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: *in vitro* evaluation and *in vivo* tumor accumulation. *Pharm Res*. 2010a;27(1):161–74. Submitted: July 27, 2009.
- Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, *et al*. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. *Biomaterials*. 2010b;31(6):1360–71. Submitted: August 21, 2009.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11095-009-9992-1>.

S. Zhu • M. Hong • L. Zhang • G. Tang • Y. Jiang (✉) • Y. Pei
Department of Pharmaceutics, School of Pharmacy, Fudan University
826 Zhangheng Road
Shanghai 201203, China
e-mail: yanyanjiang@shmu.edu.cn